JaLCDOI 10.18926/AMO/54423
FullText URL 70_3_223.pdf
Author Ebara, Shin| Kobayashi, Yasuyuki| Sasaki, Katsumi| Araki, Motoo| Sugimoto, Morito| Wada, Koichirou| Fujio, Kei| Takamoto, Atsushi| Watanabe, Toyohiko| Yanai, Hiroyuki| Nasu, Yasutomo|
Abstract The present case report describes a case of recurrent and advanced urachal carcinoma including neuroendocrine features with iliac bone metastasis after partial cystectomy and adjuvant chemotherapy consisting of irinotecan and cisplatin in a 32-year-old man. He received gemcitabine/cisplatin/ paclitaxel (GCP) combination chemotherapy, consisting of gemcitabin (1,000mg/m2) on day 1, 8, cisplatin (70mg/m2) on day 1, and paclitaxel (80mg/m2) on day 1 and 8. After three cycles of chemotherapy, PET-CT showed complete regression of the disease. So the patient underwent total cystourethrectomy, and histological examination showed an almost complete pathological response. External beam radiation therapy was also given to the ileac bone metastasis regions. However, PET-CT taken 17 months after the external beam radiation showed multiple lung metastases. He received GCP chemotherapy again, which resulted in a complete response again after three cycles of chemotherapy. This is the first report on GCP chemotherapy used not only as a salvage chemotherapy but also as a rechallenge regimen for metastatic urachal cancer including a neuroendocrine component.
Amo Type Case Report
Published Date 2016-06
Publication Title Acta Medica Okayama
Volume volume70
Issue issue3
Publisher Okayama University Medical School
Start Page 223
End Page 227
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 27339213
Web of Sience KeyUT 000379406100011
JaLCDOI 10.18926/AMO/54507
FullText URL 70_4_295.pdf
Author Araki, Motoo| Wada, Koichiro| Mitsui, Yosuke| Kubota, Risa| Yoshioka, Takashi| Ariyoshi, Yuichi| Kobayashi, Yasuyuki| Kitagawa, Masashi| Tanabe, Katsuyuki| Sugiyama, Hiroshi| Wada, Jun| Watanabe, Masami| Watanabe, Toyohiko| Hotta, Katsuyuki| Nasu, Yasutomo|
Abstract Although graft survival following renal transplantation (RTx) has improved, outcomes following highrisk RTx are variable. Preexisting antibodies, including donor-specific antibodies (DSA), play an important role in graft dysfunction and survival. We have designed a study to investigate the safety and efficacy of anti-CD20 monoclonal antibodies (rituximab) in high-risk RTx recipients. Major eligibility criteria include: 1) major and minor ABO blood group mismatch, 2) positive DSA. Thirty-five patients will receive 200 mg/body of rituximab. The primary endpoint is the incidence of B cell depletion. This study will clarify whether rituximab is efficacious in improving graft survival in high-risk RTx recipients.
Keywords end-stage renal disease immunosuppression kidney transplantation
Amo Type Clinical Study Protocols
Published Date 2016-08
Publication Title Acta Medica Okayama
Volume volume70
Issue issue4
Publisher Okayama University Medical School
Start Page 295
End Page 297
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 27549676
Web of Sience KeyUT 000384748600011
JaLCDOI 10.18926/AMO/54508
FullText URL 70_4_299.pdf
Author Wada, Koichiro| Uehara, Shinya| Ishii, Ayano| Sadahira, Takuya| Yamamoto, Masumi| Mitsuhata, Ritsuko| Takamoto , Atsushi| Araki, Motoo| Kobayashi, Yasuyuki| Watanabe, Masami| Watanabe, Toyohiko| Hotta, Katsuyuki| Nasu, Yasutomo|
Abstract Urinary tract infections (UTIs) are the most common bacterial infections in women, and many patients experience frequent recurrence. The aim of this report is to introduce an on-going prospective phase II clinical trial performed to evaluate the preventive effectiveness of Lactobacillus vaginal suppositories for prevention of recurrent cystitis. Patients enrolled in this study are administered vaginal suppositories containing the GAI 98322 strain of Lactobacillus crispatus every 2 days or 3 times a week for one year. The primary endpoint is recurrence of cystitis and the secondary endpoints are adverse events. Recruitment began in December 2013 and target sample size is 20 participants.
Keywords probiotics lactobacilli Lactobacillus crispatus urinary tract infection vaginal suppository
Amo Type Clinical Study Protocols
Published Date 2016-08
Publication Title Acta Medica Okayama
Volume volume70
Issue issue4
Publisher Okayama University Medical School
Start Page 299
End Page 302
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 27549677
Web of Sience KeyUT 000384748600012
Author Nasu, Yasutomo|
Published Date 2016-12-01
Publication Title Journal of Okayama Medical Association
Volume volume128
Issue issue3
Content Type Journal Article
Author Waki, Takahiro| Katsui, Kuniaki| Mitsuhashi, Toshiharu| Ogata, Takeshi| Katayama, Norihisa| Takemoto, Mitsuhiro| Nasu, Yasutomo| Kumon, Hiromi| Kanazawa, Susumu|
Published Date 2017-02
Publication Title Acta Medica Okayama
Volume volume71
Issue issue1
Content Type Journal Article
JaLCDOI 10.18926/AMO/54823
JaLCDOI 10.18926/AMO/54976
FullText URL 71_2_91.pdf
Author Ogawa, Nanako| Sato, Shuhei| Ida, Kentaro| Kato, Katsuya| Ariyoshi, Yuichi| Wada, Koichiro| Nasu, Yasutomo| Kanazawa, Susumu|
Abstract The aim of this study was to investigate the utility of single-source dual-energy computed tomography (SS-DECT) composition analysis in characterizing different types of urinary stones and differentiating them from phleboliths. This study included 29 patients with urinary stones who were scheduled for surgery. All patients were scanned, first using single-energy computed tomography acquisition and then DECT acquisition on SS-DECT. Dual-energy data were archived to a Gemstone spectral imaging (GSI) viewer (GE Healthcare, Milwaukee, WI, USA). Hounsfield units (HU) and effective atomic numbers (Zeff) were estimated using the GSI viewer. The results of dual-energy analysis were compared with the biochemical constitution of the stones. The chemical analysis determined that the stones included 32 calcium-based, 6 cystine and 1 struvite stone. Both HU and Zeff values were helpful in differentiating calcium-based stones from cystine and struvite stones and phleboliths. The Zeff values of phleboliths were significantly higher than those for struvite and cystine stones, whereas it was difficult to distinguish phleboliths from struvite and cystine stones using the HU values. Composition analysis using SS-DECT is helpful for distinguishing urinary stone types and discriminating phleboliths from urinary stones. Zeff values may be more useful than HU values for differentiating urinary stones from phleboliths.
Keywords single-source dual-energy computed tomography effective atomic number urinary stone phlebolith
Amo Type Original Article
Published Date 2017-04
Publication Title Acta Medica Okayama
Volume volume71
Issue issue2
Publisher Okayama University Medical School
Start Page 91
End Page 96
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2017 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 28420889
JaLCDOI 10.18926/AMO/54982
FullText URL 71_2_135.pdf
Author Mori, Akihiro| Watanabe, Masami| Sadahira, Takuya| Kobayashi, Yasuyuki| Ariyoshi, Yuichi| Ueki, Hideo| Wada, Koichiro| Ochiai, Kazuhiko| Li, Shun-Ai| Nasu, Yasutomo|
Abstract The cluster of differentiation 147 (CD147), also known as EMMPRIN, is a key molecule that promotes cancer progression. We previously developed an adenoviral vector encoding a tumor suppressor REIC/Dkk-3 gene (Ad-REIC) for cancer gene therapy. The therapeutic effects are based on suppressing the growth of cancer cells, but, the underlying molecular mechanism has not been fully clarified. To elucidate this mechanism, we investigated the effects of Ad-REIC on the expression of CD147 in LNCaP prostate cancer cells. Western blotting revealed that the expression of CD147 was significantly suppressed by Ad-REIC. Ad-REIC also suppressed the cell growth of LNCaP cells. Since other researchers have demonstrated that phosphorylated mitogen-activated protein kinases (MAPKs) and c-Myc protein positively regulate the expression of CD147, we investigated the correlation between the CD147 level and the activation of MAPK and c-Myc expression. Unexpectedly, no positive correlation was observed between CD147 and its possible regulators, suggesting that another signaling pathway was involved in the downregulation of CD147. This is the first study to show the downregulation of CD147 by Ad-REIC in prostate cancer cells. At least some of the therapeutic effects of Ad-REIC may be due to the downregulation of the cancer-progression factor, CD147.
Keywords prostate cancer REIC/Dkk-3 CD147 cell growth p38 MAP kinase
Amo Type Original Article
Published Date 2017-04
Publication Title Acta Medica Okayama
Volume volume71
Issue issue2
Publisher Okayama University Medical School
Start Page 135
End Page 142
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2017 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 28420895
JaLCDOI 10.18926/AMO/54989
FullText URL 71_2_187.pdf
Author Takamoto, Atsushi| Araki, Motoo| Wada, Koichiro| Sugimoto, Morito| Kobayashi, Yasuyuki| Sasaki, Katsumi| Watanabe, Toyohiko| Nasu, Yasutomo|
Abstract We report the case of a 58-year-old Japanese man with bilateral synchronous renal cell carcinoma (RCC). The diameters of the right and left tumors were 56 and 69 mm, respectively. Both tumors were endophytic. Cryoablation with prophylactic embolization was performed for the left tumor, and 1 month later, a right open partial nephrectomy was performed. No recurrence was observed during a 16-month follow-up, and the serum creatinine level has been stable. The prognosis of bilateral synchronous RCC is better than that of dialysis patients. The novel approach of combining cryoablation and partial nephrectomy can achieve good cancer control and renal function in bilateral RCC.
Keywords cryoablation multiple renal masses nephron-sparing surgery renal cell carcinoma synchronous multiple primary
Amo Type Case Report
Published Date 2017-04
Publication Title Acta Medica Okayama
Volume volume71
Issue issue2
Publisher Okayama University Medical School
Start Page 187
End Page 190
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2017 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 28420902
JaLCDOI 10.18926/AMO/55205
FullText URL 71_3_227.pdf
Author Sasaki, Katsumi| Wada, Koichiro| Araki, Motoo| Kobayashi, Yasuyuki| Sugimoto, Morito| Ebara, Shin| Watanabe, Toyohiko| Nasu, Yasutomo|
Abstract  We elucidate the fate of cases clinically suspected of carcinoma in situ (Cis) of the upper tract with serial ureteroscopy. Of 143 patients who underwent ureteroscopy for suspected upper tract urothelial carcinoma (UTUC) between January 2008 and February 2016, 12 cases with consistently positive urine cytology and poorly detectable upper-tract malignancies by imaging were reviewed. In these 12 patients, 19 ureteroscopy procedures (25 renal units) were performed. Vesical random biopsy was performed before the 1st ureteroscopy to exclude malignancy of the bladder in all 12 cases. Median follow-up was 42 (13-67) months. Positive biopsy results at the 1st ureteroscopy were obtained in 3 (25%) patients and all were diagnosed wth Cis of the upper tract. Two (17%) of 9 patients who were negative or inconclusive at the 1st ureteroscopy were finally diagnosed as UTUC, but plural ureteroscopy procedures were needed for the diagnoses in both. Carcinoma of the bladder appeared in 5 (42%) patients during follow-up, despite the earlier ruling out of vesical malignancy. Four (33%) of those 5 patients never developed upper-tract urothelial carcinoma during follow-up. Caution is required before undertaking radical surgery for cases clinically suspected of Cis of the upper tract. In our experience, only 42% of such patients developed UTUC; another 33% eventually developed carcinoma of the bladder without UTUC.
Keywords carcinoma in situ carcinoma of the bladder upper tract urothelial carcinoma ureteroscopy urine cytology
Amo Type Original Article
Published Date 2017-06
Publication Title Acta Medica Okayama
Volume volume71
Issue issue3
Publisher Okayama University Medical School
Start Page 227
End Page 232
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2017 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 28655942